Endometrial ablation can be performed by several different minimally invasive procedures which cause surgical destruction of the endometrium to treat abnormal uterine bleeding (AUB). First generation technique involves the use of a resectoscope with direct visualization of the endometrial cavity. The resectoscopic technique has become less common with the introduction of non-resectoscopic techniques that use various energy sources including bipolar radiofrequency and heated water to accomplish global endometrial destruction. Both types of procedures appear equivalent in reduction of menstrual bleeding and patient satisfaction. Approximately 30-40% of women report amenorrhea at 1 year and and 50% at 2-5 years following ablation. Patient satisfaction with the procedure is quite high, ranging from 80-90%.
Endometrial ablation is primarily intended to treat premenopausal women with heavy menstrual bleeding (HMB) who do not desire future fertility. Women who choose endometrial ablation often have failed or declined medical management. Absolute contraindications to endometrial ablation include pregnancy, known or suspected endometrial hyperplasia or cancer, desire for future fertility, active pelvic infection, IUD currently in situ, and being post-menopausal. In general, endometrial ablation should be avoided in patients with congenital uterine anomalies, severe myometrial thinning, and uterine cavity lengths that exceed the capacity of the ablative technique (usually greater than 10-12 cm). Progestin therapy or correction of anovulation is recommended instead of endometrial ablation for women with chronic anovulation because of concerns about hyperplasia.
Women who desire endometrial ablation should be made aware of all medical and surgical options to treat AUB. Women should be informed that amenorrhea is not guaranteed with endometrial ablation and that reduction or normalization of menstrual flow is more likely. Endometrial ablation is an effective alternative to hysterectomy for AUB. Risks of the procedure in general and related to the specific ablative technique should be reviewed pre-operatively, including failure and post-ablation pain. Approximately 25% of patients who have had an endometrial ablation undergo a hysterectomy within 5 years of their ablation for treatment of persistent AUB or pain. Predictors of treatment failure include age < 45, parity > 5, pre-operative dysmenorrhea, and a history of tubal ligation. Women who have had a tubal ligation are at risk of post-ablation tubal sterilization syndrome, a condition characterized by cyclic pelvic pain due to residual active endometrium near the cornua leading to obstructed hematometra.
The pre-operative evaluation requires assessment of the structure and histology of the endometrium. Women should have endometrial sampling prior to ablation. The uterine cavity should be evaluated for length and presence of structural anomalies and intracavitary lesions, which can be done with uterine sounding, ultrasound, saline infusion sonogram, or hysteroscopy. Women who elect to proceed with endometrial ablation must be counseled about the need for contraception as ablation does not reliably prevent pregnancy. Pregnancies following ablation have been associated with adverse outcomes including fetal malpresentation, preterm delivery, growth restriction, abnormal placentation, and perinatal mortality.
ACOG Committee on Practice Bulletins, ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Reaffirmed 2019 Obstet Gynecol. 2007 May;109(5):1233-48 PMID: 17470612 DOI: 10.1097/01.AOG.0000263898.22544.cd
Famuyide A. Endometrial Ablation. J Minim Invasive Gynecol. 2018 Feb;25(2):299-307. doi: 10.1016/j.jmig.2017.08.656. Epub 2017 Sep 6.
Leathersich SJ and McGurgan PM. Endometrial resection and global ablation in the normal uterus. Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:84-98. doi: 10.1016/j.bpobgyn.2017.09.006. Epub 2017 Sep 28.
Initial Approval: March 2019; Reaffirmed November 2020; Reaffirmed May 2022
********** Notice Regarding Use ************
The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2022 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.Back to Search Results